Pharma Mar Achieves Legal Win in Aplidin Case

Pharma Mar SA (ES:PHM) has released an update.

Pharma Mar SA scores a legal victory as the European Commission’s decision to deny marketing authorization for its drug Aplidin is revoked, leading to a dismissal of court proceedings. The company successfully argued a conflict of interest in the original evaluation, and now the European Medicines Agency will re-evaluate the drug for multiple myeloma. The European Commission is ordered to cover its legal costs and those of Pharma Mar.

For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.